We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZTS icon
51
Zoetis
ZTS
$32.4B
$11.1M 0.42%
81,121
-70,831
-47% -$9.25M
ELV icon
52
Elevance Health
ELV
$81.5B
$10.6M 0.4%
40,242
-25,326
-39% -$6.76M
WELL icon
53
Welltower
WELL
$169B
$10.5M 0.4%
203,083
– –
BAX icon
54
Baxter International
BAX
$13.5B
$10.5M 0.4%
122,023
+24,840
+26% +$2.16M
ARGX icon
55
argenx
ARGX
$53.4B
$10.1M 0.39%
44,977
– –
AGIO icon
56
Agios Pharmaceuticals
AGIO
$1.79B
$10M 0.38%
186,964
– –
TEVA icon
57
Teva Pharmaceuticals
TEVA
$40.8B
$9.69M 0.37%
785,851
– –
ALLO icon
58
Allogene Therapeutics
ALLO
$649M
$9.25M 0.35%
216,069
-28,192
-12% -$1.02M
BPMC
59
DELISTED
Blueprint Medicines
BPMC
$9.22M 0.35%
118,256
-21,080
-15% -$1.43M
OHI icon
60
Omega Healthcare
OHI
$15.1B
$9.11M 0.35%
306,433
– –
MRTX
61
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.99M 0.34%
78,784
– –
GSK icon
62
GSK
GSK
$104B
$8.98M 0.34%
176,210
+10,716
+6% +$550K
NVO
63
Novo Nordisk
NVO
$208B
$8.78M 0.33%
268,010
– –
DOC
64
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.69M 0.33%
495,733
– –
ASND icon
65
Ascendis Pharma A/S
ASND
$16B
$8.5M 0.32%
57,482
-11,850
-17% -$1.63M
HCA icon
66
HCA Healthcare
HCA
$87.2B
$8.14M 0.31%
83,833
– –
COR icon
67
Cencora
COR
$60.6B
$8.13M 0.31%
80,645
+26,538
+49% +$2.44M
RETA
68
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.94M 0.3%
50,907
+15,778
+45% +$2.4M
KYNB
69
Kyntra Bio
KYNB
$27.2M
$7.87M 0.3%
7,771
– –
LH icon
70
Labcorp
LH
$25B
$7.85M 0.3%
55,000
+18,422
+50% +$2.55M
NVCR icon
71
NovoCure
NVCR
$1.73B
$7.81M 0.3%
131,637
+24,199
+23% +$1.59M
MPT
72
Medical Properties Trust
MPT
$2.77B
$7.74M 0.29%
411,743
– –
UTHR icon
73
United Therapeutics
UTHR
$25.8B
$7.68M 0.29%
63,513
– –
RARE icon
74
Ultragenyx Pharmaceutical
RARE
$2.45B
$7.63M 0.29%
97,480
– –
VTR icon
75
Ventas
VTR
$48B
$7.62M 0.29%
208,108
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.